Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial.
Ulrik Niels Lassen
No relevant relationships to disclose
Steen Knudsen
Employment or Leadership Position - Medical Prognosis Institute
Stock Ownership - Medical Prognosis Institute
Pernille Braemer Hertel
No relevant relationships to disclose
Iben Kumler
No relevant relationships to disclose
Dorte Nielsen
No relevant relationships to disclose
Bent Ejlertsen
No relevant relationships to disclose
Morten Mau Soerensen
No relevant relationships to disclose
Nils Brunner
No relevant relationships to disclose
Ulla Hald Buhl
Employment or Leadership Position - Medical Prognosis Institute
Stock Ownership - Medical Prognosis Institute
Mogens Winkel Madsen
Employment or Leadership Position - Liplasome Pharma
Stock Ownership - Liplasome Pharma
Ida Kappel Buhl
Stock Ownership - Medical Prognosis Institute (I)
Research Funding - Medical Prognosis Institute
Anker Hansen
Employment or Leadership Position - Medical Prognosis Institute
Stock Ownership - Medical Prognosis Institute
Thomas Jensen
Employment or Leadership Position - Medical Prognosis Institute
Stock Ownership - Medical Prognosis Institute
Eva Balslev
No relevant relationships to disclose
Jon Askaa
Employment or Leadership Position - Medical Prognosis Institute
Peter Michael Vestlev
No relevant relationships to disclose
Anne-Vibeke Laenkholm
No relevant relationships to disclose
Peter Buhl Jensen
Employment or Leadership Position - Medical Prognosis Institute
Stock Ownership - Medical Prognosis Institute